From 18–20 November 2025, Demei Chemical Technology Co., Ltd. successfully participated in CPHI Worldwide 2025 held at Fira Barcelona, Spain. As the world's leading pharmaceutical-industry event, this year's exhibition attracted more than 1,700 exhibitors and 45,000 professional visitors from over 150 countries.
Demei showcased three newly-developed pharmaceutical intermediates—PI-301, PI-302 and PI-303—which are key precursors for anti-cancer and anti-viral APIs. The products drew strong interest due to their 99.9 % purity, low residual solvent levels and competitive commercial scale.
Key Highlights
- Over 120 face-to-face technical discussions with global buyers.
- Three strategic cooperation agreements signed worth a combined USD 8.5 million.
- Two exclusive distribution appointments for South American and Middle-Eastern markets.
- Invitation from the organizing committee to deliver a tech-talk at CPHI 2026.
Customer Feedback
“Demei’s regulatory support file (RSF) is one of the most complete we have seen from a Chinese supplier. The on-spot DMFs and stability data saved us months of internal evaluation.” — Procurement Manager, European Generic Company
The exhibition also served as a platform to introduce Demei’s upgraded green-chemistry platform, featuring continuous-flow nitration and low-temperature coupling reactions that reduce waste by 70 % compared to traditional batch processes.
Looking ahead, Demei will continue to invest in R&D and global marketing, aiming to bring more high-quality, eco-friendly pharmaceutical intermediates and catalysts to customers worldwide.